2026 Q1 -tulosraportti
88 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,82%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·15 min sittenRight after Q1, the price was up to hit 305-308 based on the result and communication to the market. Logically, the price should probably remain roughly at that level, without an upward adjustment, if they just continue what was announced at Q1 and remain positive about the development - or what??
Expectations are an upward revision. If they maintain what was announced from q1, then further declines are to be expected. 10% not unrealistic. The clarification for the year preferably -2 to -8, if this happens Novo can rise 5-8%, unfortunately no more. Novo does not have investors' trust. Things take time, and one must have time if one is a Novo shareholder- ·3 t sittenReally happy that Karbonhappy in their post further down has raised their price target to 245-260 from 220 in other posts, in under a week 👍 Nice with a new thoroughly worked-out analysis, that bodes well 😁
·9 t sittenThe concerning part The US core business is still under pressure: * Adjusted US revenue fell 11%. * Ozempic fell 8% at constant currencies. * Rybelsus fell 15%. * The diabetes business fell a total of 12%. * The adjusted gross margin fell from 83.5% to 80.6%, mainly due to lower prices. report (26).pdf Novo is thus selling more GLP-1 treatments, but receiving less payment per treatment, especially in the US. This is precisely the risk the market has been concerned about. Guidance remains weak Novo now expects in 2026: * Adjusted revenue growth: -4% to -12% * Adjusted operating profit: -4% to -12% * Free cash flow: 36–46 billion DKK. * Investments: approximately 55 billion DKK.
·11 t sittenStop yourselves. I'm tired of how every time negative things are said about novo, people attack the person instead of the argument. Are you investors or critics? In the end, it only costs ourselves if one whips up a positive atmosphere without basis in reality. One needs to get all input, including the negative. Actually grotesque that in an investor forum one plays critic; then one has truly not understood what it's about.
The man is indeed right, but clearly describes himself, but as the negative taste judge. So, a total lack of self-insight.- ·16 t sittenWhat is a bit depressing now after Friday's big fall is that if the financial report is good next week, the stock will probably only rise those percentages up to where we were before.. 330-340 dkk.I understand well that some find it depressing that there was a fall and a rise will only bring us back to where we were before the fall, but I believe Novo always holds super nice surprises. It is a solid company. I also have an ACB that is close to 400 and if I had more money to throw in I would do it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
88 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,82%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 min sittenRight after Q1, the price was up to hit 305-308 based on the result and communication to the market. Logically, the price should probably remain roughly at that level, without an upward adjustment, if they just continue what was announced at Q1 and remain positive about the development - or what??Expectations are an upward revision. If they maintain what was announced from q1, then further declines are to be expected. 10% not unrealistic. The clarification for the year preferably -2 to -8, if this happens Novo can rise 5-8%, unfortunately no more. Novo does not have investors' trust. Things take time, and one must have time if one is a Novo shareholder
- ·3 t sittenReally happy that Karbonhappy in their post further down has raised their price target to 245-260 from 220 in other posts, in under a week 👍 Nice with a new thoroughly worked-out analysis, that bodes well 😁
- ·9 t sittenThe concerning part The US core business is still under pressure: * Adjusted US revenue fell 11%. * Ozempic fell 8% at constant currencies. * Rybelsus fell 15%. * The diabetes business fell a total of 12%. * The adjusted gross margin fell from 83.5% to 80.6%, mainly due to lower prices. report (26).pdf Novo is thus selling more GLP-1 treatments, but receiving less payment per treatment, especially in the US. This is precisely the risk the market has been concerned about. Guidance remains weak Novo now expects in 2026: * Adjusted revenue growth: -4% to -12% * Adjusted operating profit: -4% to -12% * Free cash flow: 36–46 billion DKK. * Investments: approximately 55 billion DKK.
- ·11 t sittenStop yourselves. I'm tired of how every time negative things are said about novo, people attack the person instead of the argument. Are you investors or critics? In the end, it only costs ourselves if one whips up a positive atmosphere without basis in reality. One needs to get all input, including the negative. Actually grotesque that in an investor forum one plays critic; then one has truly not understood what it's about.The man is indeed right, but clearly describes himself, but as the negative taste judge. So, a total lack of self-insight.
- ·16 t sittenWhat is a bit depressing now after Friday's big fall is that if the financial report is good next week, the stock will probably only rise those percentages up to where we were before.. 330-340 dkk.I understand well that some find it depressing that there was a fall and a rise will only bring us back to where we were before the fall, but I believe Novo always holds super nice surprises. It is a solid company. I also have an ACB that is close to 400 and if I had more money to throw in I would do it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
88 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,82%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 min sittenRight after Q1, the price was up to hit 305-308 based on the result and communication to the market. Logically, the price should probably remain roughly at that level, without an upward adjustment, if they just continue what was announced at Q1 and remain positive about the development - or what??Expectations are an upward revision. If they maintain what was announced from q1, then further declines are to be expected. 10% not unrealistic. The clarification for the year preferably -2 to -8, if this happens Novo can rise 5-8%, unfortunately no more. Novo does not have investors' trust. Things take time, and one must have time if one is a Novo shareholder
- ·3 t sittenReally happy that Karbonhappy in their post further down has raised their price target to 245-260 from 220 in other posts, in under a week 👍 Nice with a new thoroughly worked-out analysis, that bodes well 😁
- ·9 t sittenThe concerning part The US core business is still under pressure: * Adjusted US revenue fell 11%. * Ozempic fell 8% at constant currencies. * Rybelsus fell 15%. * The diabetes business fell a total of 12%. * The adjusted gross margin fell from 83.5% to 80.6%, mainly due to lower prices. report (26).pdf Novo is thus selling more GLP-1 treatments, but receiving less payment per treatment, especially in the US. This is precisely the risk the market has been concerned about. Guidance remains weak Novo now expects in 2026: * Adjusted revenue growth: -4% to -12% * Adjusted operating profit: -4% to -12% * Free cash flow: 36–46 billion DKK. * Investments: approximately 55 billion DKK.
- ·11 t sittenStop yourselves. I'm tired of how every time negative things are said about novo, people attack the person instead of the argument. Are you investors or critics? In the end, it only costs ourselves if one whips up a positive atmosphere without basis in reality. One needs to get all input, including the negative. Actually grotesque that in an investor forum one plays critic; then one has truly not understood what it's about.The man is indeed right, but clearly describes himself, but as the negative taste judge. So, a total lack of self-insight.
- ·16 t sittenWhat is a bit depressing now after Friday's big fall is that if the financial report is good next week, the stock will probably only rise those percentages up to where we were before.. 330-340 dkk.I understand well that some find it depressing that there was a fall and a rise will only bring us back to where we were before the fall, but I believe Novo always holds super nice surprises. It is a solid company. I also have an ACB that is close to 400 and if I had more money to throw in I would do it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt